About LIB THERAPEUTICS INC
LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company focused on developing novel therapies to help patients achieve their LDL-C goals, particularly for those with cardiovascular disease and familial hypercholesterolemia. The company is developing lerodalcibep, a third-generation PCSK9 inhibitor, as a convenient once-monthly subcutaneous dose.
Development of novel, third-generation PCSK9 inhibitorsCreation of convenient, once-monthly subcutaneous dose therapiesClinical trial execution and data presentation at major medical conferences
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to LIB THERAPEUTICS INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.